Clinical Trials & Research

A stress signal received by the heart from fat could help protect against cardiac damage induced by obesity, a new study led by UT Southwestern researchers suggests. The finding, published online in Cell Metabolism, could help explain the “obesity paradox,” a phenomenon in which obese individuals have better short- and medium-term cardiovascular disease prognoses compared

News Clinical Trials Statement on Boosting with the Johnson & Johnson COVID-19 Vaccine NEW BRUNSWICK, N.J., August 18, 2021 – We are engaging with the U.S. FDA, CDC and other health authorities and will share new data shortly regarding boosting with the Johnson & Johnson COVID-19 vaccine. In July, Johnson & Johnson shared data demonstrating that

When he became eligible for the coronavirus vaccine in Illinois, Tom Arnold, 68, said he didn’t need any convincing. He raises cattle, hogs and chickens in Elizabeth, a small town in the state’s northwestern corner. After all, who better to understand why herd immunity matters than a herdsman? “Being a livestock producer, I’m well aware

INDIANAPOLIS, July 29, 2021 /PRNewswire/ – Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today the U.S. Food and Drug Administration (FDA) has broadened the Emergency Use Authorization (EUA) for baricitinib to allow for treatment with or without remdesivir, whereas the EUA was previously restricted to use only in combination with remdesivir. The EUA now provides for

China, August 16, 2021 – Sino Biological, Inc. (“Sino Biological” or the “Company”), a biotechnology company which provides biological research reagents and related technical contract research services, announced a successful listing on the Shenzhen Stock Exchange subsidiary ChiNext under the stock abbreviation Sino Biological and stock code 301047. A total of 17 million shares were

INDIANAPOLIS, July 29, 2021 /PRNewswire/ – Today at the Alzheimer’s Association International Conference© (AAIC© 2021), Eli Lilly and Company (NYSE: LLY) presented two new exploratory analyses of data from the Phase 2 TRAILBLAZER-ALZ study. In the first, greater amyloid plaque changes following donanemab treatment was highly associated with less cognitive decline and participants with greater plaque clearance at 24 weeks

The initials BRCA2 may be best known for a gene associated with many cases of breast cancer, and the protein encoded by the BRCA2 gene is critical to repairing breaks in DNA. The breakdown of this interaction is a hallmark of many cancers. Now, U-M scientists have determined the structure of a complex of two

TARRYTOWN, N.Y., Aug. 4, 2021 /PRNewswire/ – Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the New England Journal of Medicine (NEJM) published positive detailed results from a Phase 3 trial that assessed the ability of REGEN-COV™ (casirivimab and imdevimab) to prevent COVID-19 infection among household contacts of SARS-CoV-2 infected individuals. The trial met its primary endpoint, reducing the risk of symptomatic infections by 81%

The ongoing coronavirus disease 2019 (COVID-19) pandemic has caused the infection of over 204 million individuals with severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) and claimed more than 4.3 million lives worldwide. Scientists believe that rapid vaccination of the worlds’ population is the only effective measure to contain the pandemic. Several vaccines developed by Pfizer-BioNTech,

CHICAGO & CAMBRIDGE, Mass.–(BUSINESS WIRE) August 5, 2021 — Exicure, Inc. (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, is providing an update on the Phase 1b/2 clinical trial of cavrotolimod (AST-008) (NCT03684785). The Phase 2 stage of the trial is evaluating cavrotolimod in combination with pembrolizumab

Coordination compounds have molecular structures which consist of either one or multiple metal atoms at the center, surrounded by non-metal atoms. Their fascinating physical and chemical properties, which have significant applications in material science, depend largely on their molecular structure. Thus, a definitive analysis of their molecular structure is necessary not only for understanding their

STAMFORD, Conn., Aug. 03, 2021 (GLOBE NEWSWIRE) — SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that the Company will be evaluating mirdametinib, an investigational MEK inhibitor, in a platform study sponsored by Memorial Sloan Kettering Cancer Center (MSK)

A single cell can reveal much about the biological world through genomic sequencing. Scientists can compare a single, isolated cell to other samples, analyzing the differences and similarities to better understand how the organisms originated and evolved -; or even to discover entirely new species. However, despite the rapid development of single-cell sequencing technologies, sample

NEW YORK–(BUSINESS WIRE) August 04, 2021– Pfizer Inc. (NYSE: PFE) today announced positive top-line results from the Phase 2b/3 ALLEGRO trial evaluating oral once-daily ritlecitinib in patients with alopecia areata, an autoimmune disease driven by an immune attack on the hair follicles that causes hair loss on the scalp and can also affect the face

Alzheimer’s disease (AD) is a neurological condition leading to dementia that worsens with age as patients exhibit cognitive, memory, and psychological deficits. While current therapies focus on relieving these symptoms to some extent, AD does not have a definite prevention or cure, suggesting the need for continued efforts towards understanding the biology of the disease.

TORONTO and CHICAGO and WEDEL, Germany, Aug. 03, 2021 (GLOBE NEWSWIRE) — Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSX: MDP) (OTCQX: MEDXF) and medac GmbH (“medac”) announced today that medac, Medexus’ licensor for treosulfan, has received a Complete Response Letter (CRL) from the Food and Drug Administration (FDA) in response to its New Drug

A team of scientists has uncovered a system in the brain used in the processing of information and in the storing of memories–akin to how railroad switches control a train’s destination. The findings offer new insights into how the brain functions. “Researchers have sought to identify neural circuits that have specialized functions, but there are

TARRYTOWN, N.Y., July 30, 2021 /PRNewswire/ – Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) updated the Emergency Use Authorization (EUA) for the investigational COVID-19 antibody cocktail REGEN-COV™ (casirivimab and imdevimab). The authorization now includes post-exposure prophylaxis in people at high risk for progression to severe COVID-19, who are not fully vaccinated or are not

Since the US Food and Drug Administration (FDA) established its accelerated approval pathway for drugs in 1992, nearly half (112) of the 253 drugs authorized have not been confirmed as clinically effective, an investigation by The BMJ has found. Elisabeth Mahase, clinical reporter at The BMJ, carried out an in depth analysis of FDA data

News Clinical Trials Johnson & Johnson Statement on U.S. FDA Approval of Shelf Life Extension for Company’s COVID-19 Vaccine NEW BRUNSWICK, N.J., July 28, 2021 – We are pleased to confirm the U.S. Food & Drug Administration (FDA) has extended the shelf life for the Johnson & Johnson single-shot COVID-19 vaccine to six months. The decision

UT Southwestern faculty have discovered what appears to be an Achilles’ heel in ovarian cancers, as well as new biomarkers that could point to which patients are the best candidates for possible new treatments. The finding, published in the journal Cell, was made in part using a research tool invented in a UT Southwestern lab

SOUTH SAN FRANCISCO, Calif., July 28, 2021 (GLOBE NEWSWIRE) – Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, today announced randomization of the first subject in its SUMMIT Phase 3 efficacy trial of STS101 for the acute

The 2020 nationwide lockdown India imposed in response to the COVID-19 pandemic caused disruptions that negatively impacted women’s nutrition, according to a new study from the Tata-Cornell Institute for Agriculture and Nutrition. Published in the journal Economia Politica, the study shows that women’s dietary diversity – the number of food groups consumed – declined during

NORTH CHICAGO, Ill., July 25, 2021 /PRNewswire/ — Allergan, an AbbVie (NYSE: ABBV) company, today announced new data, including the full results from the Phase 3 GEMINI 1 clinical study, evaluating the efficacy, safety and tolerability of investigational AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment of presbyopia. Multiple data presentations at the 2021 ASCRS (American Society

Frontotemporal dementias are a group of fatal and debilitating brain disorders for which there are no cures. In an article published July 26 in Cell, Mount Sinai researchers describe how they were able to recreate much of the damage seen in a widely studied form of the disease by growing special types of cerebral organoids

Issued: London UK – GlaxoSmithKline plc (LSE/NYSE: GSK) today announced positive headline results from five studies of the Phase 3 ASCEND programme, evaluating the efficacy and safety profile of daprodustat, an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), for patients with anaemia due to chronic kidney disease (CKD). The ASCEND programme showed that daprodustat met its primary efficacy

In the evolving field of cancer biology and treatment, innovations in organ-on-a-chip microdevices allow researchers to discover more about the disease outside the human body. These organs-on-chips serve as a model of the state an actual cancer patient is in, thus allowing an opportunity to finding the correct treatment before administering it to the patient.

BOSTON–(BUSINESS WIRE)–Jul. 19, 2021– Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has begun a Phase 2 proof-of-concept (POC) study in acute pain following bunionectomy surgery with the selective NaV1.8 inhibitor VX-548 and that it expects to commence a second Phase 2 study in acute pain following abdominoplasty surgery in the coming weeks. “Based on the favorable